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Introduction  19 
The idea of early intervention (EI) services for people suffering their first episode of psychosis 20 
(FEP) was conceived as a way to improve the long-term outcomes of the illness (Falloon, 21 
1992; Falloon et al., 1996). Indeed, the results of EI services, such as the Lambeth Early Onset 22 
(LEO) (Craig et al., 2004) and OPUS (Hastrup et al., 2013), have been encouraging and led 23 
to such services becoming widely established. In a further extension of the idea, specific 24 
clinical criteria were proposed to identify people who were at high clinical risk of developing 25 
psychosis in the subsequent 1-2 years (Yung et al., 1996; Yung et al., 2006). The definition of 26 
this pre-psychosis phase in which people manifested the At Risk Mental State (ARMS) (Fusar-27 
Poli et al., 2013) was followed by claims that identification of such individuals who were at 28 
ultra-high risk (UHR) of developing psychosis, provides a valuable opportunity to prevent a 29 
substantial proportion of pre-psychotic individuals from transitioning to clinical psychosis 30 
(Yung et al., 2005). Subsequently, detection of young people with the ARMS has become a 31 
popular prevention strategy (Reddy, 2014) with the creation of ARMS clinics in mamanyjor 32 
countries around the world (Addington et al., 2008; Cannon et al., 2016; Fusar-Poli et al., 33 
2013; Yung et al., 2006).  34 
ARMS clinics are specialised mental health services for help-seeking people, who are usually 35 
aged 14-35 years old and considered to be at UHR of developing psychosis. The stated 36 
purpose of these clinics is to reduce, or deter, transitions from the ARMS state to clinical 37 
psychosis (Fusar-Poli et al., 2013; Green et al., 2011). Many studies of ARMS clinics report 38 
evidence for their benefits and provide “evidence-based recommendations” or “guidance” for 39 
the treatment of such individuals (Killackey and Yung, 2007). However, the strength of such 40 
claims has not been established (Morrison et al., 2012). The purposes of this article are two-41 
fold. First, we sought to review the robustness of the claims that ARMS clinics have the 42 
capacity to prevent transition to psychosis; and second, we aimed to raise the question of 43 
whether it may be more beneficial for prevention of psychosis to adopt a public health 44 
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approach, which in turn would target risk factors for the illness onset rather than focusing on 45 
the ARMS phase.  46 
 47 
Defining the At Risk Mental State (ARMS) phase 48 
The ARMS phase is characterised by either ‘attenuated’ psychotic symptoms, or full-blown 49 
psychotic symptoms that are brief and self-limiting (Fusar-Poli et al., 2013). It may also 50 
manifest as a significant decrease in functioning in the context of a familial (presumed genetic) 51 
risk for schizophrenia, or subtle subjective disturbances of cognitive processes, thinking, 52 
perception, moods and behaviours (Yung et al., 2003; Yung et al., 2006). To increase 53 
objectivity and diagnostic accuracy of this construct, several scales, such as the 54 
Comprehensive Assessment of At-Risk Mental States (CAARMS) (Yung et al., 2005) and the 55 
Structured Interview for Prodromal Syndromes/Scale of Prodromal Symptoms (SIPS/SOPS) 56 
(Miller et al., 2003; Woods et al., 2009) have been designed to measure these symptoms with 57 
arguably reasonable inter-rater reliability (Loewy et al., 2011).  58 
However, it has been reported that as many as 84% of those individuals who were identified 59 
as being at risk for the illness using these scales did not develop a psychotic disorder within 60 
2-3 years (i.e., these individuals are normally referred to as “false positives”) (Corcoran et al., 61 
2010). Even when the diagnosis of the ARMS was made by experienced clinicians, the false-62 
positive rate remained substantially high (47%) (Yung et al., 2008). This may suggest that the 63 
difficulty in identifying individuals with the ARMS lies in defining the construct. Indeed, it has 64 
been shown that the proportion of adolescents who meet criteria for the ARMS 65 
varies from 0.9% to 22.6% depending on slight variations in the ARMS criteria (Kelleher et 66 
al., 2012). Furthermore, attempts to identify specific biological markers of the ARMS phase 67 
and predictors of a transition from the ARMS to clinical psychosis have been unsuccessful 68 
(Castle, 2012; Wood et al., 2013). It has therefore been argued that early 69 
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intervention on the basis of the screening criteria for subclinical psychosis is not feasible in 70 
the general population (van Os, 2005). 71 
 72 
Services for the ARMS phase create useful pathways to care – but for whom? 73 
Most clinics for young people who meet criteria for the ARMS, accept referrals via a wide 74 
range of means including mental and non-mental health professionals, and non-health 75 
organisations (Fusar-Poli et al., 2013; Green et al., 2011). These teams attempt to respond to 76 
all referrals and conduct the first assessment within the first week of the referral being made. 77 
This is considerably shorter than most psychiatric services can offer. For those patients who 78 
are judged to meet criteria for the ARMS, the services provide a 2-3 year treatment plan 79 
(Green et al., 2011). 80 
However, there is a question of whether individuals who contact the ARMS services and meet 81 
criteria for the ARMS are representative of all pre-psychotic individuals. For example, Ajnakina 82 
et al. (2017) showed that those with the ARMS, who attended an ARMS clinic in South-London 83 
and later developed clinical psychosis, were more likely than those FEP patients who had not 84 
attended such a clinic, to be born in the UK and have strong family support, with migrants 85 
being less likely to access the services. Others showed that the young people who met criteria 86 
for the ARMS and attended an ARMS clinic were likely to be employed and have higher 87 
educational achievements (Addington et al., 2012; Valmaggia et al., 2015).  88 
The reason for such differences is likely to be that the ARMS services require individuals to 89 
be help-seeking. Migrants and ethnic minorities are well-known to be less trusting of mental 90 
health services than those from the host population (Morgan et al., 2006). Availability of 91 
supportive families and strong social networks, which are frequently absent in those with 92 
clinical psychotic illness (Sundermann et al., 2014), are also important factors for help-93 
seeking (Morgan et al., 2006). Moreover, to recognise “not-quite-psychotic” symptoms, the 94 
potential patients, or their relatives, need to have some knowledge 95 
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of such symptoms plus insight into their potential illness significance. It is not 96 
surprising, therefore, that those patients who have been accepted under the care of the ARMS 97 
services have better insight compared to psychosis patients who do not reach these services 98 
(Lappin et al., 2007). Another reason why prodromal samples cannot be representative of all 99 
pre-psychotic individuals is that some patients present so acutely (Ajnakina et al., 2017) that 100 
even if they were willing to accept help there is no time to intervene (Shah et al., 2017). 101 
Therefore, the evidence suggests that under current pathway configurations, services for 102 
those who meet the criteria for the ARMS appear to attract a subgroup of pre-psychotic 103 
individuals who are atypical of all those people who will develop FEP. This in turn should raise 104 
some doubts as to whether some of the benefits claimed for ARMS clinics (Valmaggia et al., 105 
2015) are actually a reflection of the population attracted to the ARMS clinics, rather than the 106 
care offered by the clinics. The nature of the unselected, representative and non-help seeking 107 
population samples remains unknown. 108 
 109 
Have the transition rates fallen? 110 
Early studies reported that 30-54% of those with the ARMS went on to develop full psychotic 111 
disorder in the following 12-24 months (Fusar-Poli et al., 2012; Miller et al., 2002; Yung et al., 112 
2003). Some more recent reports, however, have suggested that the transition rates from the 113 
ARMS phase to clinical psychosis are as low as 8-17% within a 2-year period (Morrison et al., 114 
2012; Carrion et al., 2016; Conrad et al., 2017; Malla et al., 2017). It is possible that the 115 
reduced reported transition rates may be an outcome of successful interventions implemented 116 
by ARMS clinics (McGorry et al., 2006; Nelson et al., 2016).  117 
However, it is likely that the reduced estimated transition rates are, at least in part, a 118 
consequence of other factors such as changes in characteristics of the sample or their 119 
pathways to care (Wiltink et al., 2015) as well as different definitions of what constitutes 120 
transition to psychosis employed across studies (van Os and Guloksuz, 2017). Further, van 121 
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Os (2005) highlighted that the high positive predictive values presented by some studies when 122 
predicting the transition from the ARMS phase to clinical psychosis (Miller et al., 2002; Yung 123 
et al., 2003) are actually an outcome of the sample enrichment that results from the 124 
mainstream sample selection procedures. This in turn leads to spuriously increased incidence 125 
and predictive values (van Os, 2005). In fact, when the transition rate was estimated based 126 
on the actual prevalence of the ARMS in the general population it was shown to be around 127 
1% (van Os, 2005). 128 
Another important reason why transition rates are lower than previously reported may 129 
be that the identified pre-psychotic patients are diluted in more recent studies by large 130 
numbers of patients with other psychiatric problems. This may be due to referrers realising 131 
that the clinics provide an opportunity for a rapid clinical assessment of distressed young 132 
people. A recent review suggested that over 80% of individuals referred as “at risk for 133 
psychosis” will never develop clinical psychosis (van Os and Reininghaus, 2016). This raises 134 
ethical issues relating to medication exposure and stigma among those who were false-135 
positives (Bentall and Morrison, 2002; McGlashan, 2001). Even for those individuals who were 136 
identified at UHR by the ARMS services, the evidence for effectiveness of the interventions 137 
that these prodromal clinics offer is weak (Castle, 2012). 138 
 139 
Criticisms of the ARMS Concept 140 
The assumption behind AMRS clinics is that the ARMS state is what van Os and Murray RM 141 
(2013) called a “schizophrenia light”: defined according to an (arbitrary) cut-off of psychosis 142 
severity or a (similarly arbitrary) diagnostic concept of “schizophrenia spectrum”. People can 143 
cross and re-cross this boundary several times (van Os and Murray, 2013). As the 144 
expression of psychosis naturally fluctuates in intensity and severity within individuals over 145 
time, temporary amelioration of psychosis at the time of the baseline assessment may cause 146 
these people to be wrongly assigned to the UHR group rather than the psychotic group.  147 
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Furthermore, psychotic symptoms are much more common than previously realised. 148 
Indeed, they are found in about 5% of the general population, 9% of adolescents, and 25% of 149 
people with (non-psychotic) common mental disorders (Linscott and Van Os, 2013; van Os 150 
and Reininghaus, 2016; Zammit et al., 2013). Interestingly, one study found that 16% of non-151 
psychotic young people who were assessed and found not to meet the UHR criteria made a 152 
transition to clinical psychosis (Carr, 2012). These figures vary depending on different 153 
methods of data acquisition and categorisation (David, 2010). Thus, it is difficult to define with 154 
certainty when an individual transits from pre-psychotic symptoms to the ARMS, and at the 155 
other end from the ARMS to clinical psychosis (David and Ajnakina, 2016).  156 
To further complicate matters, the symptoms that are at the core of the definition of the ARMS 157 
phase are frequently present in other mental disorders (Kelleher et al., 2012; van Os and 158 
Guloksuz, 2017). Studies of UHR groups show that they consist largely of people with 159 
common mental disorders such as anxiety and depression (Addington et al., 2017; Fusar-Poli 160 
et al., 2014). Therefore, the presence of psychotic symptoms in themselves should not be 161 
seen as an indication of the risk to making the transition to psychosis (Murray and Jones, 162 
2012).  163 
 164 
ARMS clinics are morphing into clinics for youth mental health 165 
The realisation that the most common diagnoses reported in young people attending the 166 
ARMS clinics are anxiety, depression and personality disorders (Kelleher et al., 2012) 167 
prompted McGorry, one of the founders of the ARMS movement, to broaden the scope of such 168 
clinics from focussing on those at risk for psychosis to becoming more general outreach clinics 169 
for youth who are at risk for any mental disorders (Malla et al., 2016; McGorry et al., 2013). 170 
Thus, the idea of specific clinics for pre-psychotic individuals has been replaced with cross-171 
diagnostic youth mental health facilities with much broader and more inclusive (and laudable) 172 
purpose of identifying and caring for young people with mental health problems (Malla et al., 173 
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2016; McGorry et al., 2013). The inclusive concept of youth mental health is broad enough to 174 
encompass any potential abnormality and does not require being either severe or specific 175 
enough to warrant a clinical diagnosis. This approach has much to commend it but an early 176 
evaluation of such services in Australia foundthat evidence of benefit was 177 
inconclusive (Hilferty et al., 2015). 178 
 179 
A Public Health Approach 180 
Can prodromal clinics ever prevent development of clinical psychosis in a significant number 181 
of pre-psychotic individuals? Ajnakina et al. (2017) carried out a comprehensive evaluation of 182 
FEP patients in an area of South-London which has had a well-developed ARMS service for 183 
more than ten years serving the same catchment area. They found that only 4.1% of FEP 184 
patients had previously made contact with ARMS services and met the ARMS criteria (most 185 
presented to FEP psychosis directly or via other routes). This very low proportion suggests 186 
that the scope for ARMS services reducing or postponing the onset of psychosis is limited as 187 
is their public health or economic impact (van Os and Guloksuz, 2017). 188 
We recognise, of course, that ARMS clinics have provided a valuable source of pre-189 
psychotic patients for research. This in turn has ignited an explosion of research findings 190 
(Anticevic et al., 2015; Cannon et al., 2015; Walker et al., 2013). For example, it has been 191 
shown that individuals with the ARMS who proceed to develop clinical psychosis have an 192 
excess capacity to synthesise striatal dopamine (DA) which increases further as they get 193 
nearer to clinical psychosis, compared to healthy controls (Howes et al., 2011) and that cortical 194 
volume loss may be accelerated in the months prior to transition (Cannon et al., 2015). 195 
Nonetheless, this does imply that the process of developing psychosis has already begun in 196 
people with the ARMS. Therefore, it reinforces the point that intervening at this stage may 197 
already be too late.  198 
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The development of ARMS clinics has also increased awareness of a greater opportunity for 199 
prevention and early intervention. In medicine, preventive approaches to illnesses such as 200 
heart disease,  bronchitis, or obesity do not focus on identifying individuals just 201 
on the brink of developing the disorder or carrying biological markers for it. Instead, they target 202 
the known risk factors for the conditions, and encourage members of 203 
the general public to change their behaviour, for example start exercising or reduce calorie or 204 
cigarette intake, with the aim of reducing their risk of developing the condition.  205 
A similar approach should be adopted for psychosis. Indeed, a number of risk factors for 206 
developing psychosis have been identified and replicated. These include obstetric events, 207 
childhood adversity, urban birth and upbringing, and adverse life events  208 
(Gaag et al., 2016; Radua et al., 2018; Stilo and Murray, 2010). Moreover, a recent large and 209 
methodological rigorous study has provided further empirical evidence for the link between 210 
risk for psychosis onset and immigration (Jongsma et al., 2018). 211 
 212 
The evidence that cannabis use is an important risk factor for later developing psychotic 213 
symptoms and/or psychotic disorder is especially strong (Murray et al., 2016). This risk has 214 
been shown to increase linearly with a greater frequency, longer length of use, and the 215 
stronger potency of the cannabis used (Di Forti et al., 2014; Marconi et al., 2016). Importantly, 216 
it has been demonstrated that a substantial proportion of first episode psychosis cases 217 
(24% in London) would have been prevented if no one consumed cannabis of high potency 218 
(Di Forti et al., 2015). The risk increasing effects of cannabis extend to individuals 219 
who meet criteria for ARMS, reiterating the importance of this risk factor for preventative 220 
purposes. Indeed, it has been reported that individuals meeting 221 
criteria for ARMS not only have high rates of cannabis use (Carney et al., 2017) but also that 222 
those who have used cannabis at least weekly have significantly more severe positive 223 
psychotic symptoms than non-cannabis users (Nieman et 224 
al., 2016).  225 
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In the long-term, attempts to reduce exposure to these risk factors for psychosis 226 
should be made. Though this will not be easy since the pathogenic mechanism underlying the 227 
link between some of these risk factors and psychosis is not yet understood; for example, 228 
it is likely that urban living is a proxy for one or more more specific psychotogenic factor(s). 229 
Furthermore, it may be very difficult to diminish exposure to some risk factors eg child abuse 230 
or migration. However, an obvious place to start is by attempting to reduce society’s 231 
consumption of high-potency cannabis through public education (Gage et al., 2016; Di Forti et 232 
al., 2015). Unfortunately, the legalisation of cannabis for “medicinal” or “recreational” use 233 
across states of the USA has been accompanied by an increase in 234 
the use and potency of cannabis (Rehm and Fischer, 2015; Heslin et al, 2018). Thus, public 235 
policy in North America appears to be moving in the opposite direction. Psychiatrists need to 236 
be more vocal in drawing attention to the risks to mental health involved in policies which 237 
increase consumption of high potency cannabis. 238 
 239 
Conclusion 240 
The idea of identifying individuals before they become unwell is a worthy idea, especially in 241 
the era when our treatments for psychosis are far from perfect. However, it is clear that the 242 
task of making a major contribution to the prevention of psychosis is beyond the power of the 243 
ARMS clinics. A public health approach to prevention of psychosis has the potential to be 244 
more effective. Nonetheless, should such the ARMS clinic continue to exist, they face an 245 
important challenge in regard to developing pathways which will attract a broader and more 246 
representative group of individuals to access their services.  247 
 248 
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